163 related articles for article (PubMed ID: 37428211)
1. A multicenter, single-arm, open study of neoadjuvant or conversion atezolizumab in combination with chemotherapy in resectable small cell lung cancer (Cohort Study).
Duan H; Shi L; Shao C; Wang Y; Wang Z; Ni Y; Zhao J; Sun J; Tong L; Lei J; Jiang T; Liu Z; Yan X
Int J Surg; 2023 Sep; 109(9):2641-2649. PubMed ID: 37428211
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
[TBL] [Abstract][Full Text] [Related]
3. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
4. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer.
Rusch VW; Nicholas A; Patterson GA; Waqar SN; Toloza EM; Haura EB; Raz DJ; Reckamp KL; Merritt RE; Owen DH; Finley DJ; McNamee CJ; Blasberg JD; Garon EB; Mitchell JD; Doebele RC; Baciewicz F; Nagasaka M; Pass HI; Schulze K; Johnson A; Bunn PA; Johnson BE; Kris MG; Kwiatkowski DJ; Wistuba II; Chaft JE; Carbone DP; Lee JM
J Thorac Cardiovasc Surg; 2023 Mar; 165(3):828-839.e5. PubMed ID: 36369159
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Bellmunt J; Hussain M; Gschwend JE; Albers P; Oudard S; Castellano D; Daneshmand S; Nishiyama H; Majchrowicz M; Degaonkar V; Shi Y; Mariathasan S; Grivas P; Drakaki A; O'Donnell PH; Rosenberg JE; Geynisman DM; Petrylak DP; Hoffman-Censits J; Bedke J; Kalebasty AR; Zakharia Y; van der Heijden MS; Sternberg CN; Davarpanah NN; Powles T;
Lancet Oncol; 2021 Apr; 22(4):525-537. PubMed ID: 33721560
[TBL] [Abstract][Full Text] [Related]
7. A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
Andrini E; Lamberti G; Mazzoni F; Riccardi F; Bonetti A; Follador A; Artioli F; Genova C; Barbieri F; Frassoldati A; Brighenti M; Colantonio I; Pasello G; Ficorella C; Cinieri S; Tiseo M; Gelsomino F; Tognetto M; Rihawi K; Ardizzoni A
Future Oncol; 2022 Mar; 18(7):771-779. PubMed ID: 35068173
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T
Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Provencio M; Nadal E; Insa A; García-Campelo MR; Casal-Rubio J; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Pereira E; Royuela A; Casarrubios M; Salas Antón C; Parra ER; Wistuba I; Calvo V; Laza-Briviesca R; Romero A; Massuti B; Cruz-Bermúdez A
Lancet Oncol; 2020 Nov; 21(11):1413-1422. PubMed ID: 32979984
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Felip E; Altorki N; Zhou C; Csőszi T; Vynnychenko I; Goloborodko O; Luft A; Akopov A; Martinez-Marti A; Kenmotsu H; Chen YM; Chella A; Sugawara S; Voong D; Wu F; Yi J; Deng Y; McCleland M; Bennett E; Gitlitz B; Wakelee H;
Lancet; 2021 Oct; 398(10308):1344-1357. PubMed ID: 34555333
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection in patients with stage I-IIIA small-cell lung cancer: a retrospective single-arm clinical trial.
Liu J; Wang L; Shu W; Zhang L; Wang Y; Lv W; Zhu L; Hu J
J Thorac Dis; 2022 Nov; 14(11):4405-4415. PubMed ID: 36524062
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Forde PM; Spicer J; Lu S; Provencio M; Mitsudomi T; Awad MM; Felip E; Broderick SR; Brahmer JR; Swanson SJ; Kerr K; Wang C; Ciuleanu TE; Saylors GB; Tanaka F; Ito H; Chen KN; Liberman M; Vokes EE; Taube JM; Dorange C; Cai J; Fiore J; Jarkowski A; Balli D; Sausen M; Pandya D; Calvet CY; Girard N;
N Engl J Med; 2022 May; 386(21):1973-1985. PubMed ID: 35403841
[TBL] [Abstract][Full Text] [Related]
14. Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review.
Zhou N; Chen Y; Huang Q; Jiang L; Liao H; Gou H; Lu Y; Che G; Zhang Y
Front Immunol; 2023; 14():1111325. PubMed ID: 36911701
[TBL] [Abstract][Full Text] [Related]
15. Surgery for limited-stage small-cell lung cancer.
Barnes H; See K; Barnett S; Manser R
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011917. PubMed ID: 28429473
[TBL] [Abstract][Full Text] [Related]
16. Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer.
Kim SH; Jo EJ; Mok J; Lee K; Kim KU; Park HK; Lee MK; Eom JS; Kim MH
Korean J Intern Med; 2023 Mar; 38(2):218-225. PubMed ID: 36800677
[TBL] [Abstract][Full Text] [Related]
17. Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133).
Nishio M; Sugawara S; Atagi S; Akamatsu H; Sakai H; Okamoto I; Takayama K; Hayashi H; Nakagawa Y; Kawakami T
Clin Lung Cancer; 2019 Nov; 20(6):469-476.e1. PubMed ID: 31466854
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
[TBL] [Abstract][Full Text] [Related]
19. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L; Mansfield AS; Szczęsna A; Havel L; Krzakowski M; Hochmair MJ; Huemer F; Losonczy G; Johnson ML; Nishio M; Reck M; Mok T; Lam S; Shames DS; Liu J; Ding B; Lopez-Chavez A; Kabbinavar F; Lin W; Sandler A; Liu SV;
N Engl J Med; 2018 Dec; 379(23):2220-2229. PubMed ID: 30280641
[TBL] [Abstract][Full Text] [Related]
20. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE).
Yan X; Duan H; Ni Y; Zhou Y; Wang X; Qi H; Gong L; Liu H; Tian F; Lu Q; Sun J; Yang E; Zhong D; Wang T; Huang L; Wang J; Chaoyang Wang ; Wang Y; Wan Z; Lei J; Zhao J; Jiang T
Int J Surg; 2022 Jul; 103():106680. PubMed ID: 35595021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]